LGBTQ+ seniors are also affected by problematic rhetoric and language that belittles and dehumanizes queer experiences, says a leader of SAGE ...
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Needham & Company LLC reiterated their hold rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report report published on Wednesday,Benzinga reports. Other equities ...
Highlights,Institutional investors have adjusted their holdings in Sage Therapeutics.,The company reported a negative net ...
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
11d
Hosted on MSNSage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/YSage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks ...
Canaccord Genuity has adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) by reducing the stock's price target to $8.00 from the previous $9.00, while maintaining a Hold rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results